Sort
82,697 grants matching “vaccine development”
Task A45: Cotton Rat Model for the Evaluation of Vaccines and Therapeutics for RSV and Related Viruses
$984,564Steve Hauschild · Sigmovir Biosystems, Inc. · N01 · FY2020 · AI
Operations Core
$984,552William Paul Duprex · University Of Pittsburgh At Pittsburgh · UC7 · FY2023 · AI
HERPESVIRUSES AS VACCINE VECTORS FOR AIDS
$984,549Harvard University (Medical School) · P01 · FY2003 · AI
Project 2- Mechanism of How Vaccine-Elicited CD4+ T Cells Attenuate Antibody Mediated Protection
$984,538George K Lewis · University Of Maryland Baltimore · P01 · FY2016 · AI
Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors
$984,409Upendra Marathi · 7 Hills Pharma, Llc · R44 · FY2020 · CA
Chiang Mai University HIV/AIDS Clinical Trials Unit
$984,268Thira Sirisanthana · Chiang Mai University · U01 · FY2010 · AI
Modeling Inflammation in HIV Transmission
$984,098Christopher Miller · University Of California At Davis · R01 · FY2013 · AI
Cross-Protective Multivalent Vaccine for Tick-Borne Flaviviruses
$984,053David E. Clements · Hawaii Biotech, Inc. · R44 · FY2020 · AI
Role of HIV Envelope Proteins In Viral Replication and HIV Pathogenesis
$984,045Anthony S. Fauci · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
Interaction of HIV envelope with cell surface receptors
$984,045Anthony S. Fauci · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
Primate Studies
$983,967James Gibson Else · Dana-Farber Cancer Inst · P01 · FY2009 · AI
Los Angeles Pediatric AIDS Clinical Trials Unit
$983,776University Of California Los Angeles · U01 · FY2004 · AI
DNA 3.0: Development of a novel, efficient and cost-effective enzymatic process for synthesis of DNA oligonucleotides
$983,775Helge Zieler · Primrose Bio, Inc. · R44 · FY2023 · HG
Drug Injection Surveillance and Care Enhancement for Rural Northern New England (DISCERNNE)
$983,737William Edward Soares · Baystate Medical Center, Inc. · UH3 · FY2021 · DA
Development of Coccidioides Cytokine Release Assay
$983,736Eric Holbrook · Miravista Diagnostics, Llc · R44 · FY2024 · AI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS): UNIVERSAL INFLUENZA RESEARCH EFFORTS
$983,724Richard Webby · St. Jude Children'S Research Hospital · N01 · FY2018 · AI
Targeting HIV reservoirs in children with HIVIS DNA and MVA-CMDR vaccines
$983,724Merlin L Robb · Henry M. Jackson Fdn For The Adv Mil/Med · U01 · FY2024 · AI
An epitope-focused nanoparticle vaccine for anthrax
$983,698David C Whitacre · Vlp Biotech, Inc. · R44 · FY2021 · AI
Prevention Umbrella for MSM in the Americas
$983,589Susan Buchbinder · Public Health Foundation Enterprises · R01 · FY2010 · AI
Multivalent Adjuvant Immunization to Prevent Hospital Acquired Infections
$983,543Brad J Spellberg · Exbaq Llc · R42 · FY2024 · AI
Attenuated Sporozoite Malaria Vaccine
$983,532Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2011 · AI
The longevity and nature of the anti-SARS-CoV-2 cellular and humoral immune responses
$983,100Michel C Nussenzweig · Rockefeller University · P01 · FY2023 · AI
Coronavirus neutralizing antibody epitopes and immunogens
$983,100Paul D Bieniasz · Rockefeller University · P01 · FY2023 · AI
Scientific Core: BSL3 Virology and Animal Models
$983,100Charles M. Rice · Rockefeller University · P01 · FY2023 · AI
Effects of genetic polymorphism in MHC, KIR, and related loci on human disease
$983,087Mary N. Carrington · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA